FinancialGovernment SolutionsLegalReuters News AgencyRisk Management SolutionsTax & AccountingBlog: Answers OnInnovation @ Thomson Reuters
Directory of sites
Login
Contact
Support
Top News
Detained in Myanmar
North Korea
Reuters Investigates
Tech
The Wider Image
The Road to Brexit
Syria
Sports
Commentary
Pictures
Healthcare
March 29, 2018 / 1:34 PM / 24 days ago

BRIEF-Jilin Province Huinan Changlong Bio-Pharmacy Co Says FY Revenue RMB645.3 Mln

Reuters Staff

1 Min Read

March 29 (Reuters) - Jilin Province Huinan Changlong Bio-Pharmacy Co Ltd:

* FY REVENUE RMB645.3 MILLION VERSUS RMB654.1 MILLION

* FY ‍PROFIT ATTRIBUTABLE RMB144.4 MILLION VERSUS RMB142.7 MILLION Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

© 2018 Reuters. All Rights Reserved.